S040 Late-Breaking Research: Session 2
DESCRIPTION
The Late Breaking Abstract sessions invite investigators to submit their most recent unpublished research in all areas of dermatology. Following a competitive review, the highest-rated studies will be selected for brief oral presentations. The session will highlight practice-changing clinical trials, population-based studies, transformative technologies, translational biomarker research, and groundbreaking basic science. Topics covering skin, hair, and nail disorders will be considered, with a focus on findings that advance our understanding of disease mechanisms, therapy development, or adverse event prevention.
LEARNING OBJECTIVES
Discuss how the latest research findings can translate into improved patient care, focusing on new treatments, diagnostic tools, and emerging trends in dermatology.
Describe how scientific discoveries and technological advancements in dermatology can be practically integrated into everyday clinical practice, addressing both common and complex dermatologic conditions.
Discuss insights into cutting-edge industry developments, including new pharmaceutical products, devices, and technologies, and how these innovations might shape the future of dermatological treatments.
SCHEDULE
1:00 PM
Efficacy and Safety of a Highly Selective Oral TYK2 Inhibitor, ICP-488, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Double-blinded, Placebo-Controlled Trial
Xiaoguang Zhang
1:12 PM
Clinicopathologic Features and Outcomes of Hypopigmented Mycosis Fungoides in Adults: A Retrospective Multicenter Analysis
Jongbin Park
1:24 PM
Efficacy and safety of ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of adult with severe alopecia areata (AA): a randomized, double-blind, placebo-controlled phase 3..
Jianzhong Zhang, MD
1:36 PM
Utilizing Laser-Assisted Drug Delivery as a Non-Surgical Treatment for Keratinocyte Carcinomas
Ciaran T Smythe, DO
1:48 PM
Efficacy, safety, pharmacokinetics, and pharmacodynamics of HS-20137 in patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase II study
Furen Zhang, PhD, MD
2:00 PM
Rocatinlimab Significantly Improved Clinical Signs and Symptoms by Targeting OX40R+ T cells in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 ROCKET HORIZON Trial
Emma Guttman, MD, PhD, FAAD
2:12 PM
Identification of risk factors for acral melanoma in the veteran population
Jonathan Hwang
2:24 PM
Efficacy and Safety of a Novel TYK2 Inhibitor D-2570 in Patients with Moderate to Severe Plaque Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Ling Zhang
2:36 PM
Briquilimab demonstrates rapid, clinically meaningful reduction in disease activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study
Martin Metz, MD
2:48 PM
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid: Results From LIBERTY-BP ADEPT Phase 2/3 Study
Frederic Caux, PhD
3:00 PM
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-to-Target, Multi-Center Phase...
Melinda Gooderham, MD, FAAD
3:12 PM
PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: Interim Results from an Ongoing Study of INTASYL PH-762
Mary C. Spellman, MD, FAAD
3:24 PM
Efficacy and safety of upadacitinib in the treatment of palmoplantar pustulosis and construction of palmoplantar pustulosis mouse model
Yuling Shi, MD, PhD
3:36 PM
Systemic Inflammatory and Cardiovascular Abnormalities Characterize patients with Extensive Keloids, Correlating with Disease Severity
Jonathan Bar, MD
3:48 PM
Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 36-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Thierry Passeron, MD, PhD
DIRECTOR
Hensin Tsao, MD, PhD, FAAD
CO-DIRECTORS
Murad Alam, MD, FAAD
Kristina Patrice Callis-Duffin, MD, FAAD
Robert Paul Dellavalle, MD, PhD, FAAD
Joel M. Gelfand, MD, MSCE, FAAD
Kenneth B. Gordon, MD, FAAD
Sewon Kang, MD, FAAD
Paul Nghiem, MD, PhD, FAAD
Sandy Sharon Tsao, MD, FAAD
SPEAKERS
Jonathan Bar, MD
Frederic Caux, PhD
Melinda Gooderham, MD, FAAD
Emma Guttman, MD, PhD, FAAD
Jonathan Hwang
Martin Metz, MD
Jongbin Park
Thierry Passeron, MD, PhD
Yuling Shi, MD, PhD
Ciaran T Smythe, DO
Mary C. Spellman, MD, FAAD
Furen Zhang, PhD, MD
Jianzhong Zhang, MD
Ling Zhang
Xiaoguang Zhang
HANDOUTS
DISCLOSURES
Murad Alam, MD, FAAD
No financial relationships exist with ineligible companies.
Jonathan Bar, MD
No financial relationships exist with ineligible companies.
Kristina Patrice Callis-Duffin, MD, FAAD
AbbVie – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria), Stockholder Public Company(No Compensation Received); Alumis – Investigator(Grants/Research Funding); Amgen – Advisory Board(Honoraria), Consultant(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Advisory Board(Honoraria), Consultant(Fees); Celgene Corporation – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant(Honoraria), Investigator(Grants/Research Funding); FIDE – Consultant (1099 relationship)(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Novartis – Consultant(Honoraria), Investigator(Grants/Research Funding); Oruka Therapeutics – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); UCB – Stockholder Public Company(No Compensation Received);
Frederic Caux, PhD
arGEN-X – Investigator(Fees); Boehringer Ingelheim – Advisory Board(Honoraria); Eli Lilly – Speaker(Honoraria); Galderma – Advisory Board(Honoraria); LEO Laboratories Ltd (LEO Pharma) – Speaker(Honoraria); Regeneron – Investigator(Fees); Sanofi – Advisory Board(Honoraria), Speaker(Honoraria);
Robert Paul Dellavalle, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Joel M. Gelfand, MD, MSCE, FAAD
AbbVie – Consultant(Fees); Amgen – Investigator(Grants/Research Funding); Artax Biopharma – Data Safety Monitoring Board(Fees); BMS – Consultant(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); CellDex – Data Safety Monitoring Board(Fees); Daavlin Company – Other(Equipment); FIDE – Consultant(Fees); Healio – Other(Fees); Inmagene Biopharmaceuticals – Data Safety Monitoring Board(Fees); International Psoriasis Council – Board of Directors(No Compensation Received); Janssen Pharmaceuticals, Inc – Consultant(Honoraria); Leo Pharma Inc – Consultant(Fees); Maui Derm – Speaker/Faculty Education(Fees); Medical Dermatology Society – Board of Directors(No Compensation Received); Moonlake – Data Safety Monitoring Board(Fees); National Psoriasis Foundation – Investigator(Grants/Research Funding); Neuroderm LTD – Other(Fees); Novartis Pharmaceuticals Corp. – Consultant(Honoraria), Investigator(Grants/Research Funding); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); UCB – Other(Fees); Veolia North America – Consultant(Fees);
Melinda Gooderham, MD, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Acelyrin – Investigator(Grants/Research Funding); Amgen – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); AnaptysBio – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Aristea Therapeutics – Investigator(Grants/Research Funding); ASLAN Pharmaceuticals – Investigator(Grants/Research Funding); Bausch Health – Consultant(Honoraria), Investigator(Grants/Research Funding); Boehringer Ingelheim – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Bristol-Myers Squibb – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Cara Therapeutics – Investigator(Grants/Research Funding); Dermavant Sciences – Investigator(Grants/Research Funding); Eli Lilly and Company – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker/Faculty Education(Honoraria); Galderma Laboratories, LP – Investigator(Grants/Research Funding), Speaker(Honoraria); Incyte – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Inmagene Biopharmaceuticals – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Leo Pharma Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Leo Pharma Inc. – Speaker(Honoraria); Meiji Seika Pharma Co., Ltd – Investigator(Grants/Research Funding); Moonlake – Investigator(Grants/Research Funding); Nimbus Therapeutics – Investigator(Grants/Research Funding); Novartis Pharmaceuticals Corp. – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Regeneron – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Reistone Biopharma – Investigator(Grants/Research Funding); Sanofi Genzyme – Consultant(Honoraria), Speaker(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Tarsus – Investigator(Grants/Research Funding); UCB – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Ventyx Biosciences – Investigator(Grants/Research Funding); VYNE Therapeutics – Investigator(Grants/Research Funding);
Kenneth B. Gordon, MD, FAAD
AbbVie – Consultant(Honoraria), Investigator(Grants/Research Funding); Almirall – Consultant(Honoraria); Amgen – Consultant(Honoraria); Arcutis, Inc. – Consultant(Honoraria); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Dermavant Sciences – Consultant(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Leo Pharma Inc – Consultant(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Novartis Pharmaceuticals Corp. – Advisory Board(Honoraria); Othro Dermatologics – Consultant(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Protagonist Therapeutics – Consultant (1099 relationship)(Honoraria); Sanofi Genzyme – Consultant(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); UCB – Consultant(Honoraria);
Emma Guttman, MD, PhD, FAAD
AbbVie – Consultant(Fees), Consultant(Honoraria); Almirall – Consultant(Fees); Amgen – Consultant(Fees), Investigator(Grants/Research Funding); AnaptysBio – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Apogee Therapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Apollo Therapeutics Ltd – Investigator(Grants/Research Funding); Artax Biopharma – Consultant (1099 relationship)(Fees); Astria Therapeutics – Consultant (1099 relationship)(Fees); Bambusa Therapeutics Inc – Consultant (1099 relationship)(Fees); Biolojic Design – Consultant (1099 relationship)(Fees); Bionyra Pharma – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant(Fees); Bristol-Myers Squibb – Advisory Board(Honoraria), Consultant(Fees); Celldex – Consultant (1099 relationship)(Fees); Cue Biopharma – Consultant (1099 relationship)(Fees); CytoReason – Consultant (1099 relationship)(Fees); DBV Technologies – Consultant (1099 relationship)(Fees); Dualitas Therapeutics – Consultant (1099 relationship)(Fees); Electra Therapeutics – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Enveda Biosciences – Consultant (1099 relationship)(Fees); Evommune, Inc. – Consultant (1099 relationship)(Fees); Galderma Research & Development, LLC – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); Generate Biomedicines – Consultant (1099 relationship)(Fees); Gilead Sciences, Inc – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); Infimmune – Consultant (1099 relationship)(Fees); Inmagene Biopharmaceuticals – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Janssen – Consultant (1099 relationship)(Fees); Jasper Therapeutics – Consultant (1099 relationship)(Fees); Kymera Therapeutics – Consultant (1099 relationship)(Fees); Kyowa Hakko Kirin Pharma, Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); Leo Pharma Inc – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding); Matchpoint Therapeutics – Consultant (1099 relationship)(Fees); Merck – Consultant(Fees), Consultant(Honoraria); Navigator Medicines – Consultant (1099 relationship)(Fees); Nektar Therapeutics – Consultant (1099 relationship)(Fees); Opsidio – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding); Propeller Bio – Consultant (1099 relationship)(Fees); Proteologix US Inc – Consultant (1099 relationship)(Fees); RAPT Therapeutics – Consultant (1099 relationship)(Fees), Consultant (1099 relationship)(Honoraria), Consultant (1099 relationship)(Stock Options), Investigator(Grants/Research Funding); RayThera – Consultant (1099 relationship)(Fees); Regeneron – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding); Rubedo Life Sciences – Consultant (1099 relationship)(Fees); Sanofi – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding); SATO Pharmaceutical Co., Ltd – Consultant(Fees); Sitryx – Consultant (1099 relationship)(Fees); Sun Pharma Advanced Research Company (SPARC) – Consultant (1099 relationship)(Fees); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Fees); Teva – Consultant (1099 relationship)(Fees); TRex Bio – Consultant (1099 relationship)(Fees); Triveni Bio – Consultant (1099 relationship)(Fees); UCB – Consultant(Fees), Investigator(Grants/Research Funding); Ventyx Biosciences – Consultant (1099 relationship)(Fees); VeraDermics Inc. – Consultant (1099 relationship)(Fees); VRG Therapeutics – Consultant (1099 relationship)(Fees); Xencor – Consultant (1099 relationship)(Fees);
Jonathan Hwang
No financial relationships exist with ineligible companies.
Sewon Kang, MD, FAAD
Allergan, Inc – Advisory Board(Honoraria); CeraVe/Valeante – Advisory Board(Honoraria); Eli Lilly and Company – Advisory Board(Honoraria); Estee Lauder – Advisory Board(Honoraria); Galderma USA – Advisory Board(Honoraria); Incyte Corporation – Data Safety Monitoring Board(Fees); Rapalogix Health – Advisory Board(Stock Options); Walgreens Boots Alliance, Inc. – Investigator(Grants/Research Funding);
Martin Metz, MD
AbbVie – Speaker(Honoraria); Alk-Abelló – Speaker/Faculty Education(Honoraria); Almirall – Speaker(Honoraria), Speaker/Faculty Education(Honoraria); Amgen – Advisory Board(Honoraria); Arcutis Biotherapeutics – Advisory Board(Honoraria); argenx – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); AstraZeneca – Advisory Board(Honoraria); Astria Therapeutics – Advisory Board(Honoraria); Attovia Therapeutics – Consultant (1099 relationship)(Honoraria); Blueprint Medicines – Advisory Board(Honoraria); Celldex – Advisory Board(Honoraria); Celltrion – Speaker(Honoraria); Deep Apple Therapeutics – Advisory Board(Honoraria); Eli Lilly – Advisory Board(Honoraria); Escient Pharmaceuticals, Inc – Advisory Board(Honoraria); Evommune, Inc. – Advisory Board(Honoraria); Galderma – Advisory Board(Honoraria), Speaker(Honoraria); GlaxoSmithKline Immunology – Advisory Board(Honoraria); Granular Therapeutics – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); Jasper Therapeutics – Advisory Board(Honoraria); Johnson & Johnson Pharmaceutical Research & Development – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria), Speaker(Honoraria); Pfizer Inc. – Speaker(Honoraria); RAPT Therapeutics – Advisory Board(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria), Speaker(Honoraria); Santa Ana Bio – Advisory Board(Honoraria); Septerna – Advisory Board(Honoraria);
Paul Nghiem, MD, PhD, FAAD
Almirall – Consultant(Honoraria); Bristol-Myers Squibb – Investigator(Grants/Research Funding); EMD Serono – Consultant(Fees); Merck & Co., Inc – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria);
Jongbin Park
No financial relationships exist with ineligible companies.
Thierry Passeron, MD, PhD
AbbVie – Advisory Board(Honoraria), Speaker/Faculty Education(Honoraria); Almirall – Advisory Board(Honoraria); Amgen – Consultant(Honoraria); Astellas Pharma US, Inc – Investigator(Grants/Research Funding); Beiersdorf, Inc. – Speaker(Honoraria); Bioderma – Speaker/Faculty Education(Honoraria); Celgene Corporation – Investigator(Grants/Research Funding); Cutera, Inc. – Advisory Board(Honoraria); Galderma Research & Development, LLC – Advisory Board(Honoraria); GlaxoSmithKline – Speaker/Faculty Education(Honoraria); Hyphens Pharma – Speaker/Faculty Education(Honoraria); Incyte Corporation – Investigator(Fees), Speaker/Faculty Education(Honoraria); ISDIN – Advisory Board(Honoraria), Speaker(Honoraria); Janssen-Cilag – Advisory Board(Honoraria), Speaker/Faculty Education(Honoraria); Journal of the European Academy of Dermatology and Venereology – Other(No Compensation Received); L'Oréal Research and Innovation – Speaker/Faculty Education(Honoraria); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(Honoraria); Leo Pharma Inc. – Speaker/Faculty Education(Honoraria); Lilly ICOS LLC – Speaker/Faculty Education(Honoraria); Mesoestetic USA Laboratories – Advisory Board(Honoraria); MSD – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Speaker/Faculty Education(Honoraria); Symrise – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); Vichy Laboratoires – Advisory Board(Honoraria), Speaker(Honoraria); VYNE Therapeutics – Advisory Board(Honoraria);
Yuling Shi, MD, PhD
No financial relationships exist with ineligible companies.
Ciaran T Smythe, DO
Allergan – Other(Non-accredited CME Education Grant); American Academy of Dermatology – Other(Fees); American Society of Dermatologic Surgery – Other(Fees); Biofrontera – Investigator(Grants/Research Funding); Castle Biosciences – Other(Residency/Fellowship Program Funding); Cockerell Dermatopathology – Other(Residency/Fellowship Program Funding); Dermatology Times (MMM MultiMedia Medical, LLC) – Advisory Board(Honoraria); Dermsquared – Other(Non-accredited CME Education Grant), Speaker(Fees); Johnson and Johnson – Advisory Board(Honoraria); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Texas Dermatological Society – Other(Other Financial Benefit); YoungMD Connect – Other(Non-accredited CME Education Grant);
Mary C. Spellman, MD, FAAD
Azitra Inc – Consultant (1099 relationship)(Other Financial Benefit); Castle Creek Pharmaceuticals – Consultant (1099 relationship)(Other Financial Benefit); Phio Pharmaceuticals Inc – Consultant (1099 relationship)(Other Financial Benefit); Rubedo Life Sciences – Consultant (1099 relationship)(Other Financial Benefit);
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria); Worldcare Clinical, LLC – Consultant (1099 relationship)(Fees);
Sandy Sharon Tsao, MD, FAAD
Beiersdorf, Inc. – Consultant (1099 relationship)(Honoraria); Epiphany Dermatology – Advisory Board(Stock); WorldCare Clinical LLC – Consultant (1099 relationship)(Honoraria);
Furen Zhang, PhD, MD
No financial relationships exist with ineligible companies.
Jianzhong Zhang, MD
No financial relationships exist with ineligible companies.
Ling Zhang
No financial relationships exist with ineligible companies.
Xiaoguang Zhang
No financial relationships exist with ineligible companies.